Citadel Advisors
TAK icon

Citadel Advisors’s Takeda Pharmaceutical TAK Stock Holding History

Citadel Advisors’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28M Sell
1,509,500
-65,400
-4% -$1.15M ﹤0.01% 1931
2025
Q4 		$24.6M Sell
1,574,900
-33,800
-2% -$483K ﹤0.01% 2133
2025
Q3 		$23.6M Buy
1,608,700
+757,800
+89% +$11.3M ﹤0.01% 2130
2025
Q2 		$13.2M Buy
850,900
+800,300
+1,582% +$11.8M ﹤0.01% 2670
2025
Q1 		$752K Sell
50,600
-1,628,800
-97% -$22.8M ﹤0.01% 7584
2024
Q4 		$22.2M Sell
1,679,400
-16,000
-0.9% -$220K ﹤0.01% 2057
2024
Q3 		$24.1M Buy
1,695,400
+831,200
+96% +$11.8M ﹤0.01% 1853
2024
Q2 		$11.2M Sell
864,200
-897,700
-51% -$11.9M ﹤0.01% 2640
2024
Q1 		$24.5M Buy
1,761,900
+813,600
+86% +$11.8M ﹤0.01% 1866
2023
Q4 		$13.5M Sell
948,300
-5,500
-0.6% -$78K ﹤0.01% 2461
2023
Q3 		$14.8M Buy
953,800
+879,900
+1,191% +$13.6M ﹤0.01% 2205
2023
Q2 		$1.16M Sell
73,900
-43,900
-37% -$719K ﹤0.01% 6153
2023
Q1 		$1.94M Sell
117,800
-87,500
-43% -$1.39M ﹤0.01% 5447
2022
Q4 		$3.2M Buy
205,300
+44,500
+28% +$622K ﹤0.01% 4647
2022
Q3 		$2.09M Sell
160,800
-15,500
-9% -$216K ﹤0.01% 5514
2022
Q2 		$2.48M Sell
176,300
-1,100
-0.6% -$15.7K ﹤0.01% 5128
2022
Q1 		$2.54M Sell
177,400
-156,900
-47% -$2.3M ﹤0.01% 5559
2021
Q4 		$4.56M Sell
334,300
-68,500
-17% -$961K ﹤0.01% 4485
2021
Q3 		$6.6M Buy
402,800
+40,100
+11% +$673K ﹤0.01% 3781
2021
Q2 		$6.1M Sell
362,700
-317,700
-47% -$5.41M ﹤0.01% 4021
2021
Q1 		$12.4M Buy
680,400
+390,749
+135% +$7.03M ﹤0.01% 2661
2020
Q4 		$5.27M Sell
289,651
-258,549
-47% -$4.54M ﹤0.01% 3592
2020
Q3 		$9.78M Sell
548,200
-65,100
-11% -$1.19M ﹤0.01% 2321
2020
Q2 		$11M Sell
613,300
-12,700
-2% -$228K ﹤0.01% 2110
2020
Q1 		$9.5M Sell
626,000
-99,800
-14% -$1.81M ﹤0.01% 1910
2019
Q4 		$14.3M Buy
725,800
+6,300
+0.9% +$121K 0.01% 1829
2019
Q3 		$12.4M Buy
719,500
+23,900
+3% +$413K 0.01% 1977
2019
Q2 		$12.3M Buy
695,600
+452,200
+186% +$8.23M 0.01% 1928
2019
Q1 		$4.96M Buy
+243,400
New +$4.9M ﹤0.01% 3010

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's TAK Position: Q1 2026 in Review

Citadel Advisors increased its Takeda Pharmaceutical (TAK) stake by 60% in Q1 2026, buying an estimated $4.11M and bringing the position to 624,160 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3052.

Citadel Advisors first reported a position in TAK in Q4 2018 and has held it in 28 quarters since. 359 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • Citadel Advisors held 624,160 shares of Takeda Pharmaceutical worth $11.6M as of Q1 2026.
  • Citadel Advisors bought 234,426 Takeda Pharmaceutical shares in Q1 2026, an estimated $4.11M.
  • Takeda Pharmaceutical made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3052 holding.
  • Citadel Advisors first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 28 quarters since.
  • 359 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.